Building a translational cancer dependency map for The Cancer Genome Atlas

Cancer dependency maps have accelerated the discovery of tumor vulnerabilities that can be exploited as drug targets when translatable to patients. The Cancer Genome Atlas (TCGA) is a compendium of 'maps' detailing the genetic, epigenetic and molecular changes that occur during the pathoge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature cancer 2024-08, Vol.5 (8), p.1176-1194
Hauptverfasser: Shi, Xu, Gekas, Christos, Verduzco, Daniel, Petiwala, Sakina, Jeffries, Cynthia, Lu, Charles, Murphy, Erin, Anton, Tifani, Vo, Andy H, Xiao, Zhiguang, Narayanan, Padmini, Sun, Bee-Chun, D'Souza, Aloma L, Barnes, J Matthew, Roy, Somdutta, Ramathal, Cyril, Flister, Michael J, Dezso, Zoltan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cancer dependency maps have accelerated the discovery of tumor vulnerabilities that can be exploited as drug targets when translatable to patients. The Cancer Genome Atlas (TCGA) is a compendium of 'maps' detailing the genetic, epigenetic and molecular changes that occur during the pathogenesis of cancer, yet it lacks a dependency map to translate gene essentiality in patient tumors. Here, we used machine learning to build translational dependency maps for patient tumors, which identified tumor vulnerabilities that predict drug responses and disease outcomes. A similar approach was used to map gene tolerability in healthy tissues to prioritize tumor vulnerabilities with the best therapeutic windows. A subset of patient-translatable synthetic lethalities were experimentally tested, including PAPSS1/PAPSS12 and CNOT7/CNOT78, which were validated in vitro and in vivo. Notably, PAPSS1 synthetic lethality was driven by collateral deletion of PAPSS2 with PTEN and was correlated with patient survival. Finally, the translational dependency map is provided as a web-based application for exploring tumor vulnerabilities.
ISSN:2662-1347
2662-1347
DOI:10.1038/s43018-024-00789-y